EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Cagrilintide represents a novel approach to obesity management
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
It is intended for contrast enhancement in MRI scans
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Subscribe To Our Newsletter & Stay Updated
